Agilent Technologies, Inc.

A · NYSE · USD

Can Agilent keep growing faster than the instrument market, and hold its new pricing and margin gains, once the replacement cycle and tariff-refund benefits fade?

Last 4 earnings calls · through Q3 FY2026

Bull case

  • Ignite operating system

    Ignite has turned pricing, procurement and manufacturing discipline into a repeatable source of margin rather than a one-time cost program.

  • Instrument replacement cycle

    Instrument demand rests on aging customer fleets, so replacement purchases and share gains can keep growth ahead of the market.

  • Pharma and chip reshoring

    Pharma and semiconductor reshoring adds laboratory capacity that is built around the company's chromatography and spectroscopy tools.

  • Broadening product launches

    Recent launches across liquid chromatography, gas chromatography, mass spec and columns broaden the pipeline beyond one star product.

Bear case

  • Academic and China spending

    Growth leans on academic and government budgets that keep falling and on China, where orders swing with stimulus timing.

  • One-time tariff refunds

    The latest margin gain leaned on tariff refunds and on pricing that may be harder to repeat as input costs rise.

  • CDMO batch timing and customers

    The specialty CDMO business depends on a few large customers and lumpy batch schedules while new capacity ramps.

  • Competition and consolidation

    Competitors are larger and the industry is consolidating, which could pressure pricing and slow share gains over time.

Bull and bear points

Growth & Execution

In short: New instruments lift orders, but academic budgets and uneven China demand keep growth lumpy.

Bull · 3

  • Replacement cycle and new launches lift instrument orders

    Life Sciences and Applied Markets revenue rose 11.3% and book-to-bill has been at or above 1 for ten straight quarters, so instrument orders keep arriving ahead of revenue.

    Q3 FY2026 call

  • Full-year growth target raised twice

    Management started FY26 guiding 4% to 6% core growth and now points to 5.8% to 6%, a firmer target as year-over-year comparisons get harder in the second half.

    Tone shiftQ4 FY2025 → Q3 FY2026

  • China guidance raised from flat

    China was assumed flat for the year in November and is now expected to grow mid-single digits, and a large recurring revenue base means modest changes there move total growth.

    Tone shiftQ4 FY2025 → Q3 FY2026
Bear · 2

  • Federal research budgets still shrinking

    Academia and government keeps declining as U.S. federal research spending falls, and the weakness hits cell analysis and genomics hardest, offsetting part of the pharma strength.

    10-K, filed 2025-12-22

  • CDMO growth stalls in fourth quarter

    Management expects flattish advanced therapeutics growth in the fourth quarter against a 40% comparison, trimming total growth until Train C starts producing revenue next spring.

    Q3 FY2026 call

Profitability & Financial Strength

In short: Pricing and Ignite savings lift margins, while tariff refunds and rising input costs blur the trend.

Bull · 2

  • Pricing adds roughly 200 basis points a quarter

    Strategic pricing has run near 200 basis points each quarter in fiscal 2026, double the original full-year goal, the clearest evidence that Ignite changed how Agilent sells.

    Q3 FY2026 call

  • Cash flow funds buybacks and dividends

    The company returned $666 million to shareholders over the last year, about 53% of free cash flow, while net leverage stayed near one turn, leaving room for capacity spending and deals.

    Filed financials
Bear · 2

  • Tariff refunds flattered third-quarter margins

    A $20 million net tariff refund added about 110 basis points to operating margin and $0.06 to earnings per share; excluding it, expansion was 210 basis points, so the headline overstates the run rate.

    Q3 FY2026 call

  • Memory and freight costs pressure second-half margins

    Memory chip costs and Middle East shipping disruption are raising costs, and management is relying on Ignite procurement savings to absorb them within the second-half outlook.

    Q3 FY2026 call

Market Position

In short: Agilent leads in LC and GC instruments, but tariffs and government funding tie results to policy.

Bull · 2

  • Share gains in LC and mass spec confirmed by data

    Industry market share data shows Agilent winning in liquid chromatography and mass spec as customers replace aging fleets, so growth is coming at competitors' expense rather than only from a recovering market.

    Q2 FY2026 call

  • Policy-driven reshoring expands the lab buildout

    Reshoring orders came from five of the top ten global pharma companies in the third quarter, part of a $1 billion opportunity management expects to win at least a third of through 2030.

    Q3 FY2026 call
Bear · 2

  • Tariffs and trade policy remain a live cost

    Tariffs already in place and any new ones raise costs on instruments made or sold across borders, and mitigation so far has relied on price increases and moving manufacturing.

    10-K, filed 2025-12-22

  • Orders depend on customer capital budgets

    Much of revenue comes from instrument orders placed within the quarter that customers can delay or cancel, making results volatile and leaving little backlog cushion outside the specialty CDMO business.

    10-K, filed 2025-12-22